Core Viewpoint - The company announced a delay in the clinical trial progress of its "Tumor Biomarker Diagnostic Reagent Development Project" due to public health events and new clinical trial guidelines, pushing the project completion date to December 2026 [1] Investment Project Details - The planned investment amount for the project is 60 million yuan, funded by raised matching funds [1] - The project focuses on the development of diagnostic kits for gene mutation testing, specifically targeting genes such as EGFR, KRAS, BRAF, NRAS, ERBB2, and PIK3CA, as well as a multi-gene mutation testing kit for circulating tumor DNA [1] Impact of Delay - The delay does not involve changes to the implementation entity, method, or investment amount, and it will not affect the direction of the raised funds [1] - The company asserts that the delay will not have a substantial impact on its normal operations [1]

Core Viewpoint - Zhongyuan Harmony's stock price has shown a significant increase of 35.34% year-to-date, despite a recent decline of 1.21% over the last five trading days, indicating volatility in its performance [1][2]. Financial Performance - For the period from January to September 2025, Zhongyuan Harmony reported a revenue of 1.092 billion yuan, representing a year-on-year decrease of 9.41%. The net profit attributable to shareholders was 108 million yuan, down 19.18% compared to the previous year [2]. - The company has not distributed any dividends in the last three years, with a total payout of 37.54 million yuan since its A-share listing [3]. Stock Market Activity - As of December 19, Zhongyuan Harmony's stock was trading at 26.12 yuan per share, with a market capitalization of 12.223 billion yuan. The trading volume was 52.0034 million yuan, with a turnover rate of 0.43% [1]. - The stock has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on November 24, where it recorded a net purchase of 59.36 million yuan [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 4.06% to 34,700, with an average of 13,482 circulating shares per person, a decrease of 3.91% [2][3]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 15.25 million shares, an increase of 902,300 shares from the previous period [3].

Core Viewpoint - Zhongyuan Qihe has received orphan drug designation from the FDA for its VUM02 injection, which is intended for the treatment of idiopathic pulmonary fibrosis and acute graft-versus-host disease [2] Group 1 - The company is actively exploring and planning international collaborations in accordance with domestic and international pharmaceutical regulations [2] - The focus is on diversifying cooperation models to advance the development of its cell therapy business [2]

（文章来源：证券日报） 证券日报网讯 12月15日晚间，中源协和发布公告称，公司2025年第二次临时股东大会审议通过《关于 取消监事会并修订的议案》等多项议案。 ...

Meeting Summary - The second extraordinary general meeting of shareholders was held on December 15, 2025, at the company's conference room in Tianjin [2] - The meeting was presided over by Mr. Wang Hongqi, the vice chairman and general manager, and utilized a combination of on-site and online voting methods [2][3] Attendance - Out of 9 current directors, 6 attended the meeting, while the chairman and two independent directors were absent due to work commitments [3] - All 3 current supervisors attended the meeting, along with the acting secretary of the board and some senior executives and legal advisors [3] Resolutions Passed - The following resolutions were approved: 1. Cancellation of the supervisory board and amendment of the Articles of Association [4] 2. Revision of the rules for shareholder meetings [4] 3. Revision of the rules for board meetings [5] 4. Abolition of the rules for supervisory board meetings [5] 5. Revision of the independent director work system [5] 6. Revision of the fundraising management system [5] 7. Revision of the related party transaction management system [5] 8. Revision of the internal control system for guarantees [5] 9. Revision of the internal control system for external investments [5] Voting Results - Resolutions 1, 2, 3, and 4 required a special resolution and were passed with over two-thirds of the valid voting rights held by attending shareholders or their representatives [6] Legal Verification - The meeting was witnessed by Beijing Guofeng Law Firm, and the lawyers confirmed that the meeting's procedures complied with relevant laws and regulations [7] Financial Management - The company utilized RMB 120 million of idle raised funds for cash management, specifically investing in structured deposits with Huaxia Bank [9][10] - The company redeemed the investment on December 15, 2025, recovering the principal of RMB 120 million and earning a profit of RMB 347,178.08 [10]

中源协和细胞基因工程股份有限公司 关于使用闲置募集资金进行现金管理到期赎回的公告 公司已全部赎回用于现金管理的募集资金，不存在逾期未收回的情况。 特此公告。 证券代码：600645 证券简称：中源协和 公告编号：2025-053 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司于 2024 年 12 月 18 日召开十一届十五次临时董事会和十一届七次临时 监事会，会议审议通过了《关于使用暂时闲置募集资金及自有资金进行现金管理 的议案》。在不影响正常经营、不影响募集资金项目建设和募集资金使用计划的 前提下，同意公司及控股子公司使用不超过人民币 1.2 亿元的闲置募集资金及不 超过人民币 6 亿元的闲置自有资金进行现金管理，自公司董事会、监事会审议通 过之日起 12 个月内有效。具体详见公司公告：2024-051、052、053。 后公司使用 1.2 亿元闲置募集资金购买了华夏银行股份有限公司上海分行人 民币单位结构性存款 DWJCSH25064，公司已于 2025 年 12 月 15 日赎回上述产品， 收回本金 1.2 亿元 ...

北京国枫律师事务所 北京国枫律师事务所(以下简称"本所")接受贵公司的委托,指派律师出席并见 证贵公司 2025年第二次临时股东大会(以下简称"本次会议")。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》(以下简称"《证券法》")、《上市公司股东会规则》(以下简称 "《股东会规则》")、《律师事务所从事证券法律业务管理办法》(以下简称"《证券法律 业务管理办法》")、《律师事务所证券法律业务执业规则(试行)》(以下简称"《证券法 律业务执业规则》")等相关法律、行政法规、规章、规范性文件及《中源协和细胞基因 工程股份有限公司章程》(以下简称"《公司章程》")的规定,就本次会议的召集与召开 程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜,出具本法律 意见书。 对本法律意见书的出具,本所律师特作如下声明: 关于中源协和细胞基因工程股份有限公司 2025 年第二次临时股东大会的 法律意见书 国枫律股字[2025] A0601 号 致:中源协和细胞基因工程股份有限公司（贵公司） 1. 本所律师仅就本次会议的召集与召开程序、召集人和出席现场会议人员资格、 ...

证券代码：600645 证券简称：中源协和 公告编号：2025-052 中源协和细胞基因工程股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 190 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 112,557,534 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 24.6893 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，股东大会主持情 况等。 (一) 股东大会召开的时间：2025 年 12 月 15 日 (二) 股东大会召开的地点：天津市滨海高新区华苑产业区梅苑路 12 号公司会 议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 会议采用现场投票和网络投票相结合的表决方式，符合《公司法》和《公司 章程》的有关规定，经公司半数以上董 ...

Core Viewpoint - The company, Zhongyuan Xiehe (600645), is committed to advancing stem cell drug research and development, enhancing its R&D system, and deepening collaborations with top-tier hospitals and research institutions to establish a robust R&D technology platform [1] Group 1: R&D Strategy - The company will continue to enrich and expand its R&D pipeline, accelerating the transformation and market promotion of new products [1] - The focus will be on both domestic market development and proactive international market positioning [1] Group 2: Collaboration and Partnerships - The company aims to promote the development of cell therapy business through diversified collaboration models [1]

证券代码：600645 证券简称：中源协和 公告编号：2025-051 中源协和细胞基因工程股份有限公司 关于召开2025年第二次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 股东大会召开日期：2025年12月15日 ● 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票系统 中源协和细胞基因工程股份有限公司（以下简称"公司"）于2025年11月28日在上海证券交易所网站和 《中国证券报》、《上海证券报》、《证券时报》刊登了《关于召开2025年第二次临时股东大会的通 知》，定于2025年12月15日以现场投票和网络投票相结合的方式召开2025年第二次临时股东大会，现将 本次股东大会的相关事项提示如下： 召开地点：天津市滨海高新区华苑产业区梅苑路12号公司会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025年12月15日 一、召开会议的基本情况 (一)股东大会类型和届次 2025年第二次临时股 ...